Time for sharp competitive intelligence

Sanofi-Aventis said it is ‘considering all its legal options’ after the U.S. Court of Appeals upheld an earlier ruling in the Lovenox anti-coagulant patent infringement suit against Amphastar and Teva Pharmaceutical Industries.

As a result of the Court of Appeals ruling the U.S. Lovenox patent is deemed to be ‘unenforceable’.

While several generic manufacturers have requested marketing approval from the FDA for their products alleged to be generic versions of Lovenox, Sanofi-Aventis has not learned of any FDA approval of these requests.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Tag Cloud

%d bloggers like this: